News

Fund+ in the news
April 12, 2021

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting Additional clinical data will show benefits of leriglitazone in adrenomyeloneuropathy (AMN) Mataró, Barcelona, Spain, April 12, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan […]

Read Post
April 1, 2021

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838   NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime […]

Read Post
March 29, 2021

Michel Detheux (iTeos): ‘Biotech is als Formule 1: hoe meer geld, hoe sneller je kan gaan’

Michel Detheux (iTeos): ‘Biotech is als Formule 1: hoe meer geld, hoe sneller je kan gaan’ Michel Detheux: ‘We hebben voor de agressieve aanpak gekozen en 210 miljoen dollar opgehaald op Nasdaq. Dat was moeilijk geweest in België.’ ©M. Scott Brauer   Het Belgische biotechbedrijf Iteos Therapeutics stapte acht maanden geleden door de grote poort […]

Read Post
March 22, 2021

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million   Accelerate development of novel mRNA vaccine for hard-to-treat cancers Clinical trial to commence end of 2021   Niel, Belgium, 22 March 2021: eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies as off-the shelf products for the treatment of […]

Read Post
March 18, 2021

Indigo Diabetes Initiates First Clinical Study of its Continuous Glucose Monitoring Sensor

Indigo Diabetes Initiates First Clinical Study of its Continuous Glucose Monitoring Sensor Ground-breaking subcutaneous sensor aims to continuously monitor multiple metabolites including ketones in people living with diabetes BELGIUM – Ghent, March 18, 2021 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, announces that its continuous multi-metabolite […]

Read Post
March 16, 2021

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing   Extends Series A with additional EUR19 million led by Fund+ Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials XVR011 expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other […]

Read Post
March 9, 2021

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses • XVR011 antibody expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other Sarbecoviruses to emerge in future • Unique Llama-derived VHH72-Fc antibody (XVR011) for […]

Read Post
March 5, 2021

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases  Initial focus on development of HIV vaccine   London, United Kingdom and Niel, Belgium, March 4, 2021 – ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA […]

Read Post
March 5, 2021

ONA Therapeutics appoints Mark Throsby to its Board of Directors

ONA Therapeutics appoints Mark Throsby to its Board of Directors Barcelona, Spain, March 5th, 2021: Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today that it has appointed Dr. Mark Throsby as independent board member of its Board of Directors. Dr. Throsby is a proven […]

Read Post
March 4, 2021

Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003

Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003 – Authorization to start clinical trial in the US granted for rare paediatric bone disease Mont-Saint-Guibert, Mar 4, 2021 (GlobeNewswire) – Novadip Biosciences (“Novadip”), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, today […]

Read Post
February 18, 2021

Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis – Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline – – Primary Objective of Therapeutic Benefit Achieved in 27.3% of the Patients […]

Read Post
February 18, 2021

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery and Clinical Improvement – Primary and Key Secondary Endpoints Were Not Evaluable Due to the Very […]

Read Post
February 17, 2021

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news

Read Post
January 27, 2021

Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)

Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN) • Largest prospective efficacy study conducted in the orphan disease AMN • Leriglitazone significantly reduces progression of cerebral lesions and myelopathy symptoms • Minoryx preparing for discussions with regulators for approval of leriglitazone for AMN patients Mataró, […]

Read Post
December 18, 2020

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia   Study demonstrates leriglitazone improves relevant disease biomarkers and ataxia resulting in clinical benefit in this orphan disease   Mataró, Barcelona, Spain, December 15, 2020 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on […]

Read Post
December 14, 2020

Immunic, Inc. Added to NASDAQ Biotechnology Index

Immunic, Inc. Added to NASDAQ Biotechnology Index   NEW YORK, Dec. 14, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to […]

Read Post
December 3, 2020

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities   Niel, Belgium, December 1st, 2020: eTheRNA immunotherapies NV (“eTheRNA”) today announced it has entered into a strategic cooperation and product license agreement with China Grand Pharmaceutical & Healthcare Holdings Ltd […]

Read Post
November 16, 2020

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal Preclinical data highlights potential therapeutic action and protection against neurodegeneration Mataró, Barcelona, Spain and Gosselies, Belgium, November 16, 2020 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous […]

Read Post
November 3, 2020

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors    Development of New Treatment Conferring Broad Protection Against Coronaviruses on Track   Belgium, 3 Nov 2020: ExeVir, which is developing nanobody therapies providing broad protection against viral infections, including a lead candidate for coronaviruses, today announced that Michel Kazatchkine and Stef […]

Read Post
November 2, 2020

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed – Top-Line Data Expected in Q1 2021 – NEW YORK, Nov. 2, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral […]

Read Post
November 2, 2020

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases EIB support to develop breakthrough treatments to address orphan neurodegenerative diseases with high unmet medical needs Focus on Minoryx’s lead asset, leriglitazone, a novel, disease-modifying PPAR-γ agonist Venture debt operation supported by the Investment Plan […]

Read Post
October 21, 2020

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy   – European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic’s lead asset, IMU-838, in moderate COVID-19 – IMU-838 is an orally available small molecule, which, because of its […]

Read Post
October 15, 2020

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development   Ghent, Belgium – October 15, 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has applied its proprietary, […]

Read Post
October 9, 2020

eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development

eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development New hire will accelerate commercial development of Company’s proprietary TriMix mRNA platform for oncology and infectious disease immunotherapies   Niel, Belgium, October xx, 2020 – eTheRNA immunotherapies NV (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing immunotherapies from its proprietary mRNA […]

Read Post
September 28, 2020

Ona Therapeutics is named as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020

Ona Therapeutics is named as one of Fierce Biotech’s  “Fierce 15” Biotech Companies of 2020   Barcelona, Spain – 28 September 2020 – Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, today announced that it has been named by Fierce Biotech as one of 2020’s Fierce […]

Read Post